**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a retrospective observational single-center study of 10 patients, four patients (three women and one man) aged 30−47 years were described, who developed diarrhoea, emesis, hypokalaemia or digestive adverse reaction during treatment with lopinavir \[*routes not stated*\] for COVID-19 infection.

Patient 1: The 45-year-old woman, who was admitted with a diagnosis of COVID-19 pneumonia, started receiving treatment with lopinavir 400mg every 12 hours along with atomisation inhalation of interferon-α2b. Within 4 days after the initiation of the treatment, she developed lopinavir-related adverse effects including diarrhoea, emesis and hypokalaemia. Lopinavir was discontinued, and she started receiving treatment with umifenovir \[arbidol hydrochloride\], immune globulin \[human immunoglobulin\] and methylprednisolone with continuation of interferon-α2b. But, deterioration in radiography and clinical symptoms was observed, following which she was transferred to the First Affiliated Hospital of Zhejiang University hospital for further treatment.

Patient 2: The 30-year-old woman, who was admitted with a diagnosis of COVID-19 infection, started receiving treatment with lopinavir 400mg every 12 hours along with atomisation inhalation of interferon-α2b. Within 4 days after the initiation of the treatment, she developed lopinavir-related adverse effects including diarrhoea, emesis and hypokalaemia. Lopinavir was discontinued, and she started receiving treatment with umifenovir, immune globulin and methylprednisolone with continuation of interferon-α2b. But, deterioration in radiography and clinical symptoms was observed, following which she was transferred to the First Affiliated Hospital of Zhejiang University hospital for further treatment.

Patient 6: The 47-year-old man, who was admitted with a diagnosis of COVID-19 infection, started receiving treatment with lopinavir 400mg every 12 hours along with atomisation inhalation of interferon-α2b. Four days after the initiation of the treatment, he developed lopinavir-related digestive adverse reaction. He also developed hypokalaemia. Hence, lopinavir treatment was stopped. Thereafter, he started receiving unspecified glucocorticoid along with unspecified interferon-backbone combination regimen. On day 18 of admission, he tested negative for SARS-CoV-2-RNA, following which he was discharged.

Patient 8: The 33-year-old woman, who was admitted with a diagnosis of COVID-19 infection, started receiving treatment with lopinavir 400mg every 12 hours along with atomisation inhalation of interferon-α2b. Four days after the initiation of the treatment, she developed diarrhoea and hypokalaemia. Thereafter, lopinavir treatment was continued, and she also started receiving pantoprazole \[somac\], albumin human, umifenovir, immune globulin and methylprednisolone. In two days, a significant improvement was observed in her adverse reaction and radiographic opacities. Subsequently, her COVID-19 infection was cured, following which she was discharged \[*outcomes not stated; not all time to reactions onset stated*\].
